PDCD1 and hematologic disorder: The monocyte can be considered a maestro within the TME in both solid tumors and hematologic malignancies, moreover, the applications of checkpoint inhibitors, such as PD-1, CTLA-4, and BTLA, have emerged as a new upsurge of tumor immunotherapy.